- Corporate Officers - B
- Brumm Joshua T
Insider Trading History of Brumm Joshua T
The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Brumm Joshua T since 2015.
This trader's CIK number is 1528826.
At the time of last reporting, Brumm Joshua T was the Chief Executive Officer of Crescent Biopharma, Inc.. (stock ticker symbol CBIO).
Also see all insider trading activities at Crescent Biopharma, Inc..
Note that in the past
Brumm Joshua T also reported insider trading activities as an insider of the following companies:
Yearly summary of insider trading at Crescent Biopharma, Inc. (CBIO) by Brumm Joshua T
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2026 | CBIO | 0 | $0 | 42,305 | $761,066 | 0 | $0 |
Yearly summary of insider trading at Aravive, Inc. (VSAR) by Brumm Joshua T
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2017 | VSAR | 0 | $0 | 36,955 | $728,258 | 30,000 | $75,900 |
| 2016 | VSAR | 0 | $0 | 7,714 | $93,377 | 0 | $0 |
| 2015 | VSAR | 2,500 | $24,975 | 0 | $0 | 0 | $0 |
Yearly summary of insider trading at Dyne Therapeutics, Inc. (DYN) by Brumm Joshua T
| | Insider Buying | Insider Sales | Option Exercises |
|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
|---|
| 2024 | DYN | 0 | $0 | 808,535 | $19,547,224 | 783,062 | $3,614,527 |
| 2023 | DYN | 0 | $0 | 359,937 | $4,572,960 | 278,030 | $286,369 |
| 2022 | DYN | 0 | $0 | 213,384 | $2,659,064 | 210,000 | $216,300 |
| 2021 | DYN | 0 | $0 | 8,009 | $127,312 | 0 | $0 |
Insider trading activities at 3 companies by Brumm Joshua T:
1. Crescent Biopharma, Inc. (CBIO)
2. Aravive, Inc. (VSAR)
3. Dyne Therapeutics, Inc. (DYN)
Table 1. Insider trading of Crescent Biopharma, Inc. (CBIO) by Brumm Joshua T
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2026-06-22 | CBIO | Sale | 42,305 | 17.99 | 761,066 |
Table 2. Insider trading of Aravive, Inc. (VSAR) by Brumm Joshua T
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2017-10-19 | VSAR | Sale | 1,326 | 2.55 | 3,381 |
| 2017-06-13 | VSAR | Sale | 1,421 | 16.05 | 22,807 |
| 2017-05-16 | VSAR | Sale | 1,263 | 17.40 | 21,976 |
| 2017-02-24 | VSAR | Option Ex | 30,000 | 2.53 | 75,900 |
| 2017-02-24 | VSAR | Sale | 30,000 | 21.31 | 639,300 |
| 2017-01-30 | VSAR | Sale | 2,945 | 13.85 | 40,794 |
| 2016-12-27 | VSAR | Sale | 990 | 15.85 | 15,691 |
| 2016-12-07 | VSAR | Sale | 3,021 | 13.25 | 40,028 |
| 2016-06-15 | VSAR | Sale | 1,448 | 10.63 | 15,392 |
| 2016-05-20 | VSAR | Sale | 1,265 | 7.87 | 9,955 |
| 2015-12-30 | VSAR | Sale | 990 | 12.44 | 12,311 |
| 2015-11-12 | VSAR | Buy | 2,500 | 9.99 | 24,975 |
Table 3. Insider trading of Dyne Therapeutics, Inc. (DYN) by Brumm Joshua T
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|
| 2024-03-08 | DYN | Sale | 363,343 | 26.47 | 9,616,599 |
| 2024-03-11 | DYN | Option Ex | 50,000 | 5.54 | 277,000 |
| 2024-03-11 | DYN | Sale | 66,387 | 25.89 | 1,718,958 |
| 2024-03-08 | DYN | Option Ex | 363,343 | 5.54 | 2,012,920 |
| 2024-03-07 | DYN | Sale | 9,086 | 25.85 | 234,873 |
| 2024-02-29 | DYN | Sale | 5,520 | 27.50 | 151,800 |
| 2024-03-01 | DYN | Sale | 94,480 | 29.06 | 2,745,588 |
| 2024-02-29 | DYN | Option Ex | 5,520 | 5.54 | 30,580 |
| 2024-03-01 | DYN | Option Ex | 94,480 | 5.54 | 523,419 |
| 2024-01-04 | DYN | Option Ex | 218,536 | 3.29 | 717,890 |
| 2024-01-03 | DYN | Option Ex | 51,183 | 1.03 | 52,718 |
| 2024-01-04 | DYN | Sale | 218,536 | 18.73 | 4,092,086 |
| 2024-01-03 | DYN | Sale | 51,183 | 19.29 | 987,320 |
| 2023-12-11 | DYN | Sale | 7,585 | 10.72 | 81,311 |
| 2023-09-18 | DYN | Sale | 12,032 | 9.41 | 113,221 |
| 2023-09-12 | DYN | Sale | 7,672 | 10.41 | 79,865 |
| 2023-06-08 | DYN | Option Ex | 30,088 | 1.03 | 30,990 |
| 2023-06-09 | DYN | Option Ex | 76,582 | 1.03 | 78,879 |
| 2023-06-08 | DYN | Sale | 61,000 | 13.31 | 811,910 |
| 2023-06-09 | DYN | Sale | 76,582 | 13.34 | 1,021,603 |
| 2023-06-12 | DYN | Option Ex | 171,360 | 1.03 | 176,500 |
| 2023-06-12 | DYN | Sale | 187,748 | 12.61 | 2,367,502 |
| 2023-03-14 | DYN | Sale | 7,318 | 13.33 | 97,548 |
| 2022-10-07 | DYN | Option Ex | 14,200 | 1.03 | 14,626 |
| 2022-10-10 | DYN | Sale | 195,800 | 12.46 | 2,439,668 |
| 2022-10-10 | DYN | Option Ex | 195,800 | 1.03 | 201,674 |
| 2022-10-07 | DYN | Sale | 14,200 | 13.37 | 189,854 |
| 2022-03-11 | DYN | Sale | 3,384 | 8.73 | 29,542 |
| 2021-09-20 | DYN | Sale | 3,425 | 15.61 | 53,464 |
| 2021-09-21 | DYN | Sale | 4,584 | 16.11 | 73,848 |
Insider trading activities including stock purchases, stock sales, and option exercises
listed in the above table cannot be completely guaranteed as to their accuracy.
For more information regarding the trades made by Brumm Joshua T
(Chief Executive Officer of Crescent Biopharma, Inc. at the time of this reporting) see
the Securities and Exchange Commission (SEC) website.